Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
The group toplines a phase 2 win with Alphamedix.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
And Treeline and HengRui also get in on the pan-RAS act.
A phase 3 trial of Hernexeos in adjuvant HER2m NSCLC is planned.
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
The group’s $8bn acquisition of Merus was the standout in the third quarter.
